X

Trial Profile

A real world study of enzalutamide or abiraterone acetate in metastatic castration-resistant prostate cancer patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

14 Mar 2018 New trial record
10 Feb 2018 Results of a study comparing healthcare resource utilization and costs for patients treated with Enzalutamide or Abirateron acetate in the U.S presented at the 2018 Genitourinary Cancers Symposium
10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com